Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 27, 2020

Primary Completion Date

December 5, 2022

Study Completion Date

December 5, 2022

Conditions
Presbyopia
Interventions
DRUG

AGN-241622

Topical eye drop

DRUG

Vehicle

Topical eye drop

Trial Locations (10)

33140

Quantum Clinical Trials /ID# 237330, Miami Beach

40206

The Eye Care Institute /ID# 234507, Louisville

78229

Eye associates /ID# 236502, San Antonio

78744

PPD Clinical Research Unit - Austin /ID# 237644, Austin

90301

United Medical Research Institute /ID# 234612, Inglewood

90041-1718

Global Research Foundation /ID# 237353, Los Angeles

91345-1200

North Valley Eye Medical Group, Inc. /ID# 236686, Mission Hills

92663-3637

The Eye Research Foundation /ID# 234526, Newport Beach

66762-2620

Kannarr Eye Care /ID# 236718, Pittsburg

38119-5745

Total Eye Care, PA /ID# 234454, Memphis

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY